Controlled Human Infection Models (CHIM) are revolutionising the approach to vaccine development by offering a faster, more precise, and efficient approach to studying vaccine efficacy. 💉 🚀 There have been recent advancements in vaccine development, expedited by clinical trials conducted at hVIVO. ✨ Discover more by reading this blog: https://lnkd.in/g4vXwBn7 #HVO #CHIM #HumanChallenge #Vaccine #ClinicalTrials
hVIVO
Biotechnology Research
London, England 11,275 followers
The world leader in testing infectious and respiratory disease vaccines & therapeutics using human challenge trials.
About us
hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
- Website
-
http://www.hvivo.com
External link for hVIVO
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, England
- Type
- Public Company
- Founded
- 1989
- Specialties
- clinical trials, uk clinical trials, clinical research, challenge models, human challenge models, human volunteer research, respiratory disease research, medical research, asthma studies, copd, influenza, human models of disease, clinical research, challenge studies, human challenge trials, RSV, malaria, HRV, Respiratory syncytial virus, Human rhinoviruse, lab services, and covid 19
Locations
-
Primary
40 Bank Street
London, England E14 5NR, GB
Employees at hVIVO
Updates
-
Our Director of Clinical Operations Melanie Smyth MSc discusses the move to Canary Wharf: 👩🔬 Working at hVIVO 🏙️ How Canary Wharf benefit's clinical operations 💪 The move & impact on the team 🔬 Safety measures to ensure maximum care for volunteers Full also available on hVIVO's YouTube Channel: https://lnkd.in/eZUsYRpv #HVO #CanaryWharf #Clinical #CHIM
-
We will be heading to Vienna to attend the @ERS Congress, an annual event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science 🛫 Meet with our colleagues Egle Pavyde and Alexander Mann to discuss hVIVO’s support of field-based airway disease trials, as well as our world leading reputation for testing vaccine and drug efficacy in human challenge trials. Learn more about how our new 50 bed inpatient facility in Canary Wharf and X bed outpatient provision with supporting laboratories, all of which can help further advance respiratory medicine research 🔬 Connect 🤝with the team at the event or reach out directly to schedule a meeting! Learn more: https://lnkd.in/dWng7gC #ERS2024 #HVO #Conference #RespiratoryDisease
-
The hVIVO interim results for the six months to 30 June 2024 will be published on Tuesday 10 September. Our CEO Yamin 'Mo' Khan & CFO Stephen Pinkerton, will be presenting with Investor Meet Company at 6pm that evening. Register to attend: https://lnkd.in/e_aHRaQe #HVO #CompanyPresentation #Interims
-
Tune in to hear our CEO Yamin 'Mo' Khan's thougts on our new state-of-the-art facility in Canary Wharf. 🚗 Main drivers for the move 🏙️ Why hVIVO chose Canary Wharf 💪 How the move empowers the Company's mission 🔬 Expanding hVIVO's service offering 🙌 Employee benefits from the move The full video is also available on our #YouTube channel: https://lnkd.in/eShEpZbT #HVO #CanaryWharf #ScientificResearch
hVIVO at Canary Wharf - Yamin 'Mo' Khan
https://www.youtube.com/
-
Exciting news from Pfizer' RSV vaccine, Abrysvo, which has shown strong results in a Phase III trial for immunocompromised adults. The study demonstrated a robust neutralizing response, offering hope for those at higher risk of severe RSV complications. This could significantly impact the RSV vaccine landscape, where options for younger immunocompromised individuals are currently limited. Read full article: https://lnkd.in/eMFuKyXE #HealthcareInnovation #Vaccines #RSV #HVO
-
Our team and 6 hVIVO scientific posters are heading to the Options XII conference hosted in Brisbane, Australia. This event brings together researchers, practitioners and trailblazers from across the globe to discuss the latest advancements in #influenza control. Meet with our colleagues Yamin 'Mo' Khan, Andrew Catchpole, Nicolas Noulin Egle Pavyde, & Rich Niemi to understand how hVIVO is making a significant contribution to furthering scientific research in #influenza. Do not miss hVIVO's 6 scientific posters by Andrew Catchpole, Brandon Londt, Alexander Mann and Nicolas Noulin published at this prestigious events. We look forward to seeing you there! Learn more: https://lnkd.in/ev-64pDJ #HVO #OPTIONSXII #ControlInfluenza
-
Our grand opening of the world's largest human challenge trial unit in Canary Wharf was a great success! We were delighted to have so many industry colleagues, academics, clients and partners join us for this unveiling. 👨🔬 Guided tours of our state-of-the-art facility ✅ Presentations from management on the improved efficiencies 💪 Presentations & panel discussion with key opinion leaders 🥂 Networking session We would like to thank our guest speakers Bassam Hallis of the UK Health Security Agency, Peter Openshaw of Imperial College London, Stephen Lockhart, the hVIVO team and our attendee's for joining us in this significant day for the company. We look forward to continuing on our mission of delivering today's healthcare by empowering tomorrow's innovation. We hope you continue to follow along and stay tuned for more exciting #CanaryWharf content to come! 🚀 #HVO #London #GrandOpening #ScientificResearch
-
Interesting The Telegraph article highlights the urgent need to act now to prevent the next pandemic. There is a ‘long and worrying list’ of viruses. For example, the latest mutation of the H5N1 virus raises concerns of greater risk of human-human transmission and potentially a gradual emergence of a new pandemic. This is a reminder 🔔 that new research is still needed. Human Challenge Trials (HCT) could be our best protection against the next pandemic with their ability to significantly aid vaccine and drug efficacy testing! hVIVO has the world's largest portfolio of human challenge agents to support drug development. Read full article: https://lnkd.in/e7cRN-_R #HVO #HumanChallengeTrials #Pandemic #PandemicPrevention
We can stop the next pandemic, but only if we act now
telegraph.co.uk
-
A CHIM in your backpack 🎒 - our latest published blog, highlighting how human challenge trials support regulatory approval of travel vaccines. ✅ The evolution of travel vaccines and their role in public health ✅ An in-depth look at cholera, a significant threat in endemic regions ✅ How Vaxchora, a vaccine for cholera, was developed specifically for travellers ✅ The innovative use of Human Challenge Trials (HCTs) in vaccine development, showcasing their pivotal role in regulatory approval Discover how these trials not only serve as proof-of-concept but can also be crucial in demonstrating vaccine efficacy and safety. Read the full blog now to stay informed and prepared! ✈️🏥 https://lnkd.in/eNaHX4FG #TravelMedicine #Vaccines #PublicHealth #Cholera #HumanChallengeTrials #Vaxchora #GlobalHealth #Innovation #TravelSafety https://lnkd.in/eNaHX4FG